Although it is unclear whether UC-MSC-derived miR-342-3p can also suppress renal interstitial fibrosis, our in vivo and in vitro data suggest that UC-MSC-derived miR-342-3p may be a promising strategy for the treatment of DN, through inhibiting pyroptosis of renal tubular epithelial cells by targeting the NLRP3/Caspase1 pathway. This evidence concerns the gene NLRP3 and liver dysplastic nodule.